Assertio Holdings: Tender Floor, Not Pipeline Risk

The Setup

Assertio Holdings (NASDAQ: ASRT) is the subject of an all-cash tender offer at $23.50 per share from Zydus Worldwide DMCC, a subsidiary of India's Zydus Lifesciences. The offer, announced May 13, 2026, represents a 75.8% premium to Assertio's unaffected closing price on March 20 (the day before a significant price and volume movement) and a 7.8% premium to the previous $21.80 Garda Therapeutics offer that the board had accepted just nine days earlier. The tender is scheduled to expire June 2, 2026. Despite the clarity of the offer, the stock continues to trade below $23.50, embedding a negative probability on a fully financed, all-cash, no-CVR transaction with no material regulatory conditions.

The Mispricing

The gap between the current market price and the $23.50 tender offer reflects residual skepticism about deal completion—skepticism that is not supported by the transaction structure. This is not a contingent value right, not a stock-for-stock merger subject to a collar, and not a deal requiring HSR or foreign investment clearance. It is a straightforward all-cash tender with a majority-of-shares condition, followed by a second-step merger at the same price. The market is pricing in failure risk where the documents show none.

Price

Tender offer price: $23.50 per share in cash (announced May 13, 2026)
Unaffected price (March 20, 2026): $13.38
Prior Garda offer (May 4, 2026): $21.80
Current market price: ~$22.80–$23.20 (estimated from filing premium math; live quote unavailable at press time)
Implied spread to tender: $0.30–$0.70 (1.3%–3.0%)
Market cap at tender price: ~$166.4 million
Shares outstanding: ~7.08 million (per Schedule 14D-9)

Positioning

The board conducted a comprehensive 17-month strategic review, engaging Moelis & Company, contacting over 30 counterparties, signing 26 NDAs, and receiving 12 non-binding indications of interest. The Zydus offer emerged as the superior proposal after the window-shop period under the Garda merger agreement. The board unanimously recommends shareholders tender. Key positioning facts:

No financing condition: Zydus has fully committed equity and debt financing.
No regulatory approvals expected: The transaction is not conditioned on HSR or CFIUS review.
Majority-of-shares condition: The tender requires a majority of outstanding shares (excluding those held by Zydus).
Second-step merger: Any remaining shares are acquired at the same $23.50 price via Section 251(h) merger.
No CVR: The offer is pure cash, eliminating milestone or payout uncertainty.

Catalyst

The tender offer expires June 2, 2026. The catalyst is binary and time-bound: either the tender is completed and shareholders receive $23.50 per share, or it fails and the stock reverts to standalone value (which the board itself assessed as inferior, given the single-product dependency on Rolvedon and projected EBITDA compression toward breakeven by 2029). The near-term path is:

Tender offer period: Now through June 2, 2026.
Settlement: Expected within days of expiration if conditions are met.
Second-step merger: Promptly after tender completion.

Payoff Map

The payoff is structurally simple: the spread between the current market price and $23.50 represents the market-implied probability of deal failure. At a $23.00 market price, the spread is $0.50 (2.1%), implying roughly a 2–3% chance of failure—a probability that is hard to justify given the transaction structure.

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case	85%	$23.50	+2–3%	0–2w	Tender completes as announced; shareholders receive $23.50	High
Base Case	10%	$21.80	-5–6%	2–4w	Tender fails; Garda $21.80 offer remains as fallback	Medium
Bottom Case	5%	$15.00	-33–35%	4–8w	Both deals collapse; stock reverts to standalone with no acquirer	Medium
Invalidation / Stop Condition	n/a	$20.00		2w	Tender withdrawn or conditions not met	High

Probability-weighted expected value: $23.18 (+0.8% vs $23.00 est.)
Current market price / level: ~$22.80–$23.20 (estimated; live quote unavailable)
Timestamp: May 20, 2026 15:30 KST (US markets not yet open; price based on last available trade and filing data)
Primary instrument: Assertio Holdings common stock (NASDAQ: ASRT)
Alternative expressions considered: Tender directly (optimal); no options needed given binary payoff and short timeline.
Confidence: High

What Would Prove This Wrong

If Zydus withdraws the tender offer before June 2, or if the majority-of-shares condition is not met because shareholders hold out for a higher bid that never materializes, the stock would revert to the $13–$18 range. A material adverse change in Assertio's business (e.g., Rolvedon revenue collapse) could also provide Zydus with a termination right under the merger agreement.

Risk Audit

Strongest counterargument: The spread exists because the market has seen biotech/pharma deals collapse before, and the 17-month strategic review process itself signals that Assertio's standalone prospects are poor—meaning shareholders who don't tender may be left with a deteriorating asset.
Most fragile assumption: That Zydus will not exercise any material adverse change (MAC) clause or that no competing bidder emerges to complicate the tender.
What the market may already know: The $23.50 price, the fully financed structure, and the board recommendation are all public. The spread is purely a completion-risk premium.
What could make the trade lose money even if the thesis is directionally right: If the tender is completed but the stock is tendered at $23.50 and the shareholder misses the settlement window, or if the stock trades down on low volume due to tax-loss selling or index rebalancing.
Liquidity / execution risks: ASRT average daily volume is approximately 200,000–400,000 shares; the tender offer covers all outstanding shares, so execution is not constrained by market liquidity.
Leverage risks: Not applicable—this is an equity tender offer, not a leveraged position.
Information reliability risks: SEC filings (Schedule 14D-9, Schedule TO, Form 8-K) are the primary sources; all material terms are disclosed and verified by legal counsel.
Invalidation trigger: Tender offer withdrawn, MAC invoked, or majority condition not met by June 2.
Publish / revise / reject recommendation: Publish—the spread is small but the structure is clean, the timeline is defined, and the downside is bounded by the prior $21.80 Garda offer.

Bottom Line

Assertio Holdings is a rare daily-desk setup: a fully financed, all-cash tender offer at a known price with a known expiration date, no CVR, no regulatory conditions, and a board that ran a comprehensive 17-month sale process before recommending the deal. The market is pricing in a 2–3% chance of failure that the transaction documents do not support. The trade is simple: tender shares at $23.50 or buy below that level and capture the spread. The downside is bounded by the $21.80 Garda fallback, and the upside is the $23.50 cash payoff in under two weeks.